Our proprietary patch combines targeted local anesthesia with vessel conditioning in a single application designed for the vascular access workflow.
The Enso Vascular Patch is a topical drug-delivery platform engineered specifically for pre-procedural application at vascular access sites. Unlike systemic approaches or general-purpose topical anesthetics, our technology is purpose-built for the unique pharmacological and anatomical requirements of vascular access.
The patch delivers a proprietary combination of active pharmaceutical ingredients through the skin to the target tissue, achieving therapeutic concentrations at the depth relevant to vascular access within a clinically practical timeframe.
Optimized for intradermal and subdermal drug deposition at the tissue layers overlying the target vessel, rather than systemic transdermal absorption.
Combines two complementary therapeutic mechanisms in a single formulation to simultaneously address pain and vessel reactivity at the access site.
Designed to fit seamlessly into existing procedural workflows with a simple apply-and-wait protocol requiring no additional training or equipment.
Existing options were not designed for the vascular access use case and fail to address the specific clinical needs of pre-procedural site preparation.
The current standard causes pain itself, distorts tissue anatomy, and can induce the very vasospasm it aims to prevent. Provides anesthesia but no vessel conditioning.
Products like EMLA require 60+ minutes for adequate depth penetration and provide only anesthesia with no anti-spasm properties. Not designed for vascular access workflows.
Administered after arterial puncture, meaning they cannot prevent spasm during the initial access attempt. Requires mixing and injection — adds complexity and cost.
Purpose-built dual-action formulation providing both local anesthesia and vessel conditioning through non-invasive topical delivery. Applied pre-procedurally, works within the clinical workflow window.
Our technology platform is protected by a comprehensive intellectual property strategy encompassing the novel combination formulation, delivery methodology, and specific therapeutic application at vascular access sites.
Provisional patent protection has been filed covering the core formulation, method of use, and delivery system. The IP strategy is designed to create durable protection across the key dimensions of our competitive advantage.
The Enso Vascular Patch is being developed through an FDA regulatory pathway appropriate for combination topical drug products. Our formulation leverages well-characterized active pharmaceutical ingredients with established safety profiles, which supports an efficient development timeline.
By utilizing active ingredients with extensive existing safety data and established pharmacological profiles, we aim to streamline the regulatory pathway and reduce clinical development risk relative to novel molecular entities.